Who are SGLT2i+Metformin+Linagliptin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sglt2i-metformin-linagliptin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

SGLT2i+Metformin+Linagliptin — Competitive Intelligence Brief

SGLT2i+Metformin+Linagliptin (SGLT2i+Metformin+Linagliptin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination antidiabetic agent (SGLT2 inhibitor + biguanide + DPP-4 inhibitor). Area: Diabetes.

marketed Combination antidiabetic agent (SGLT2 inhibitor + biguanide + DPP-4 inhibitor) SGLT2 transporter, mitochondrial complex I (metformin), dipeptidyl peptidase-4 Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

SGLT2i+Metformin+Linagliptin (SGLT2i+Metformin+Linagliptin) — Huazhong University of Science and Technology. This triple-combination therapy reduces blood glucose through three complementary mechanisms: blocking renal glucose reabsorption (SGLT2i), enhancing insulin secretion and sensitivity (metformin), and inhibiting dipeptidyl peptidase-4 to prolong incretin action (linagliptin).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
SGLT2i+Metformin+Linagliptin TARGET	SGLT2i+Metformin+Linagliptin	Huazhong University of Science and Technology	marketed	Combination antidiabetic agent (SGLT2 inhibitor + biguanide + DPP-4 inhibitor)	SGLT2 transporter, mitochondrial complex I (metformin), dipeptidyl peptidase-4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination antidiabetic agent (SGLT2 inhibitor + biguanide + DPP-4 inhibitor) class)

Huazhong University of Science and Technology · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SGLT2i+Metformin+Linagliptin — Competitive Intelligence Brief. https://druglandscape.com/ci/sglt2i-metformin-linagliptin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab